Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
Author/s
author: Maricla Galetti, Anna Squadrilli, Claudia Fumarola, Silvia Monica Ess, Mara A Bonelli, Daniele Cretella, Pier Giorgio Petronini, Andrea Cavazzoni, Federico Quaini, Denise Madeddu, Marcello Tiseo, Elisabetta Barocelli, Costanza Annamaria Lagrasta, Roberta Minari
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.